FDA warned PowerAll Pharma for selling unapproved, misbranded opioid and benzodiazepine drugs online without prescriptions.
What happened
FDA reviewed PowerAll Pharma’s websites and found it offered tramadol, oxymorphone (Opana ER), and diazepam (Valium) for sale to U.S. consumers. FDA said these are unapproved new drugs and are misbranded because their labeling lacks adequate directions and they are prescription drugs offered without requiring a prescription. This was based on a website review, not an inspection.
What FDA found
PowerAll Pharma offered tramadol, oxymorphone, and diazepam as new drugs without FDA-approved applications.
FD&C Act sections 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]The drug labeling did not give adequate directions for a layperson to use the products safely.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]PowerAll Pharma offered prescription drugs without requiring a prescription, which misbrands the drugs.
FD&C Act sections 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]PowerAll Pharma caused unapproved and misbranded drugs to be introduced into interstate commerce through its websites.
FD&C Act sections 301(a), 301(d), 301(k), 503(b), 505(a) [21 U.S.C. §§ 331(a), 331(d), 331(k), 353(b), 355(a)]
What FDA wants
FDA tells PowerAll Pharma to stop offering any violative drugs for sale to U.S. consumers and to respond in writing within 15 working days describing corrective steps and how it will prevent recurrence.
Who should pay attention
- online pharmacies selling prescription opioids or benzodiazepines
- services hosting or processing payments for such websites
- consumers buying prescription drugs online
This is a summary. Read the original letter on fda.gov.